Developing predictive assays: The phenotypic screening “rule of 3”
Fabien Vincent, Paula M. Loria, Marko J. Pregel et al. · Science Translational Medicine · 2015
Phenotypic drug discovery approaches can positively affect the translation of preclinical findings to patients. However, not all phenotypic assays are created equal. A critical question then follows: What are the characteristics of the optimal assays? We analyze this question and propose three specific criteria related to the disease relevance of the assay-system, stimulus, and end point-to help design the most predictive phenotypic assays.
Cited by 199 works. doi:10.1126/scitranslmed.aab1201
Authors
- Fabien Vincent
- Paula M. Loria
- Marko J. Pregel
- Robert V. Stanton
- Linda Kitching
- Karl H. Nocka
- Régis Doyonnas
- Claire M. Steppan
- Adam M. Gilbert
- Thomas Schroeter
- Marie‐Claire Peakman
References
- Embryonic Stem Cell Lines Derived from Human Blastocysts
- Neurogenesis in the adult human hippocampus
- Raise standards for preclinical cancer research
- Believe it or not: how much can we rely on published data on potential drug targets?
- Diagnosing the decline in pharmaceutical R&D efficiency
- How were new medicines discovered?
- The Noncoding RNA Revolution—Trashing Old Rules to Forge New Ones
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- Environment Drives Selection and Function of Enhancers Controlling Tissue-Specific Macrophage Identities
- Spiroindolones, a Potent Compound Class for the Treatment of Malaria